FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558567182> ?p ?o ?g. }

• W2558567182 endingPage "48" @default.
• W2558567182 startingPage "44" @default.
• W2558567182 abstract "Neuroendocrine tumors (NETs) comprise a heterogeneous group of malignancies with various clinical presentations and evolution. NETs are often diagnosed at a late stage, when they are already metastatic. Treatment is currently based on traditional chemotherapies, such as streptozocin, with serious side effects. The favorable toxicity profile of the combination of 5-fluorouracil with oxaliplatin, together with its significant antitumor activity in several gastrointestinal malignancies, led to the evaluation of its efficacy and tolerability in patients with advanced grade 1/2 (G1/G2) NETs. The endpoints of the study were tumor response (according to the Response Evaluation Criteria in Solid Tumors 1.1), overall survival (OS), progression-free survival (PFS) and symptom improvement. From January, 2013 to January, 2015, during our Regional Multidisciplinary Tumor Board dedicated to NETs (RENATEN network), FOLFOX was recommended for the treatment of metastatic NETs as first-line therapy or after failure of other therapies. The inclusion criteria were metastatic, well-differentiated G1/G2 NETs, progressing within the last 3 months. Cases with previous antitumor therapy were allowed. The patients received modified FOLFOX-6 and were assessed every 3 months by computed tomography or magnetic resonance imaging examinations. A total of 31 patients were included. The median follow-up was 20 months [95% confidence interval (CI): 15-27]. Nine patients (29%) exhibited a partial response, and 13 (41%) achieved stable disease; the disease control rate was 70%. A total of 9 patients exhibited disease progression. The control rate was 78% for pancreatic and 65% for extrapancreatic NETs. The median OS was not reached; the 1- and 2-year OS rates were 89 and 70%, respectively (Fig. 1). No significant difference in OS was observed between the <5 and 5-20% Ki-67 subgroups (P=0.41) (Fig. 2A) or according to primary tumor location (P=0.71) (Fig. 2B). The median PFS was 14.1 months (95% CI: 9.3-24.1), with no significant difference in PFS between the Ki-67 subgroups (P=0.26) (Fig. 3A) or by primary tumor location (P=0.995) (Fig. 3B). The median time to treatment failure was 14.72 months (95% CI: 10.0-not estimable). No unusual toxicity or toxicity-related deaths were reported. Finally, 7 of 9 patients who achieved a partial response benefited from a break in treatment of ≥3 months. The median duration of this break was 9.2 months (range, 3-42 months). Of the 13 patients with stable disease, 12 may have also benefited from a chemotherapy break. The median break duration was 10 months (range, 0.5-26 months)." @default.
• W2558567182 created "2016-12-08" @default.
• W2558567182 creator A5019977580 @default.
• W2558567182 creator A5027698971 @default.
• W2558567182 creator A5046670297 @default.
• W2558567182 creator A5063086784 @default.
• W2558567182 creator A5069539916 @default.
• W2558567182 creator A5082610705 @default.
• W2558567182 date "2016-12-01" @default.
• W2558567182 modified "2023-10-13" @default.
• W2558567182 title "Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer" @default.
• W2558567182 cites W1935825021 @default.
• W2558567182 cites W1973577894 @default.
• W2558567182 cites W1981584797 @default.
• W2558567182 cites W1985795867 @default.
• W2558567182 cites W1985844593 @default.
• W2558567182 cites W1992109464 @default.
• W2558567182 cites W1992361608 @default.
• W2558567182 cites W2006821285 @default.
• W2558567182 cites W2009629472 @default.
• W2558567182 cites W2011916383 @default.
• W2558567182 cites W2024966748 @default.
• W2558567182 cites W2031366605 @default.
• W2558567182 cites W2039261671 @default.
• W2558567182 cites W2042265119 @default.
• W2558567182 cites W2052779140 @default.
• W2558567182 cites W2082472122 @default.
• W2558567182 cites W2096888043 @default.
• W2558567182 cites W2097642908 @default.
• W2558567182 cites W2107276199 @default.
• W2558567182 cites W2110922803 @default.
• W2558567182 cites W2115686439 @default.
• W2558567182 cites W2118672029 @default.
• W2558567182 cites W2121368761 @default.
• W2558567182 cites W2123060958 @default.
• W2558567182 cites W2128328462 @default.
• W2558567182 cites W2130735070 @default.
• W2558567182 cites W2133933220 @default.
• W2558567182 cites W2135049144 @default.
• W2558567182 cites W2135657152 @default.
• W2558567182 cites W2137142564 @default.
• W2558567182 cites W2148933046 @default.
• W2558567182 cites W2156229277 @default.
• W2558567182 cites W2158474413 @default.
• W2558567182 cites W2162830031 @default.
• W2558567182 cites W2166100060 @default.
• W2558567182 cites W2339290868 @default.
• W2558567182 cites W2340185896 @default.
• W2558567182 doi "https://doi.org/10.3892/mco.2016.1097" @default.
• W2558567182 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5245060" @default.
• W2558567182 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28123727" @default.
• W2558567182 hasPublicationYear "2016" @default.
• W2558567182 type Work @default.
• W2558567182 sameAs 2558567182 @default.
• W2558567182 citedByCount "19" @default.
• W2558567182 countsByYear W25585671822017 @default.
• W2558567182 countsByYear W25585671822018 @default.
• W2558567182 countsByYear W25585671822020 @default.
• W2558567182 countsByYear W25585671822021 @default.
• W2558567182 countsByYear W25585671822022 @default.
• W2558567182 countsByYear W25585671822023 @default.
• W2558567182 crossrefType "journal-article" @default.
• W2558567182 hasAuthorship W2558567182A5019977580 @default.
• W2558567182 hasAuthorship W2558567182A5027698971 @default.
• W2558567182 hasAuthorship W2558567182A5046670297 @default.
• W2558567182 hasAuthorship W2558567182A5063086784 @default.
• W2558567182 hasAuthorship W2558567182A5069539916 @default.
• W2558567182 hasAuthorship W2558567182A5082610705 @default.
• W2558567182 hasBestOaLocation W25585671821 @default.
• W2558567182 hasConcept C121608353 @default.
• W2558567182 hasConcept C126322002 @default.
• W2558567182 hasConcept C143998085 @default.
• W2558567182 hasConcept C197934379 @default.
• W2558567182 hasConcept C2776694085 @default.
• W2558567182 hasConcept C2778260052 @default.
• W2558567182 hasConcept C2778375690 @default.
• W2558567182 hasConcept C2778822529 @default.
• W2558567182 hasConcept C2779066768 @default.
• W2558567182 hasConcept C2779804826 @default.
• W2558567182 hasConcept C2779984678 @default.
• W2558567182 hasConcept C2780739268 @default.
• W2558567182 hasConcept C2780962732 @default.
• W2558567182 hasConcept C526805850 @default.
• W2558567182 hasConcept C71924100 @default.
• W2558567182 hasConcept C90924648 @default.
• W2558567182 hasConceptScore W2558567182C121608353 @default.
• W2558567182 hasConceptScore W2558567182C126322002 @default.
• W2558567182 hasConceptScore W2558567182C143998085 @default.
• W2558567182 hasConceptScore W2558567182C197934379 @default.
• W2558567182 hasConceptScore W2558567182C2776694085 @default.
• W2558567182 hasConceptScore W2558567182C2778260052 @default.
• W2558567182 hasConceptScore W2558567182C2778375690 @default.
• W2558567182 hasConceptScore W2558567182C2778822529 @default.
• W2558567182 hasConceptScore W2558567182C2779066768 @default.
• W2558567182 hasConceptScore W2558567182C2779804826 @default.
• W2558567182 hasConceptScore W2558567182C2779984678 @default.
• W2558567182 hasConceptScore W2558567182C2780739268 @default.
• W2558567182 hasConceptScore W2558567182C2780962732 @default.

• next